President Donald Trump is preparing to sign an executive order aimed at promoting research into the psychedelic compound ibogaine. This initiative is anticipated to unfold in the near future, according to sources with knowledge of the executive order.
Details of the Executive Order
The forthcoming order will encourage research but is unlikely to reclassify ibogaine. Currently, ibogaine is classified as a Schedule I controlled substance in the United States. This classification indicates that it is perceived to have no accepted medical use and a high potential for abuse.
The executive order remains in draft form, and details could change before it is finalized. Neither the White House nor the US Health and Human Services has provided comments on this matter.
Background on Ibogaine
Although ibogaine has not received approval from the US Food and Drug Administration (FDA), it is utilized in certain countries to help alleviate opioid withdrawal symptoms. This psychedelic compound is extracted from the iboga plant, found in Central Africa, and has shown promise in managing opioid cravings, anxiety, depression, and even post-traumatic stress disorder (PTSD) symptoms in veterans.
Support and Risks
- High-profile advocates of ibogaine include:
- Former Texas Governor Rick Perry
- Former Senator Kyrsten Sinema
- Podcast host Joe Rogan
Despite its potential benefits, ibogaine treatment comes with risks. Users may experience abnormal heart rhythms and vomiting during the treatment process. Typically, individuals report an initial visual phase that lasts from one to four hours. This is followed by an introspective phase that can extend from hours to several days.
This situation is developing, and El-Balad will continue to provide updates as more information becomes available.
